N/A Completed N=18 Randomized Quadruple-blind Treatment

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

Liver Failure

Source: ClinicalTrials.gov NCT00886262 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2018

Primary outcomePrimary: Change in Creatinine Levels — 0.5; 0.55 MG/DL

Summary

The purpose of this study is evaluate the medication vasopressin for its ability to preserve kidney function in patients undergoing liver transplantation.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Creatinine Levels	0.5; 0.55	—
PRIMARY Change in Urine Output	1353; 731	—
SECONDARY Count of Participants Who Needed Diuretics Postoperatively	4; 1	—
SECONDARY Count of Patient Who Need Vasopressers in the Perioperative Period	3; 4	—

Eligibility Criteria

Inclusion Criteria

> 18 years of age
undergoing liver transplant
ability to provide informed consent. If patient is unable to give informed consent i.e. hepatic encephalopathy, consent may be obtained from the patient's legally authorized representative

Exclusion Criteria

< 18 years of age
renal failure

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00886262). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.